{"id":"W4394993559","doi":"10.1080/10428194.2024.2344052","title":"Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i> mutant acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Pharmacyclics; Genentech; Swedish Orphan Biovitrum; Daiichi-Sankyo; Syndax Pharmaceuticals; Sierra Oncology; Incyte; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; Astex Pharmaceuticals; PTC Therapeutics; AstraZeneca; Celgene; Leukemia and Lymphoma Society; Astellas Pharma; Instituto Nacional de Cancerología; TG Therapeutics; Pfizer; Amgen","keywords":"Medicine; Myeloid leukemia; Oncology; Chemotherapy; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002199843,0.000935659,0.0009929569,0.0005791906,0.0001911194,0.001095335,0.0008484178,0.0009320182,0.004134965],"category_scores_gemma":[0.008607715,0.0004048568,0.003565159,0.0004958279,0.0004256693,0.001106338,0.0007459981,0.001228694,0.000183986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002994413,"about_ca_system_score_gemma":0.002228249,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006772404,"about_ca_topic_score_gemma":0.006034701,"domain_scores_codex":[0.9984639,0.001067568,0.00006350556,0.00009773958,0.0001153412,0.0001919497],"domain_scores_gemma":[0.9971102,0.002090915,0.0004345112,0.00005717016,0.00007596478,0.0002312344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.1238153,0.00245843,0.01725699,0.001877762,0.0053034,0.0008624858,0.00009975167,0.7249149,0.00373584,0.005221136,0.003018811,0.1114352],"study_design_scores_gemma":[0.02913536,0.07988039,0.05939198,0.001528561,0.02415294,0.002320672,0.0004785433,0.7749842,0.007369812,0.01352913,0.006939241,0.0002891522],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818871,0.004330407,0.003718107,0.001356052,0.0001375433,0.0006114358,0.001652542,0.00007485619,0.006231936],"genre_scores_gemma":[0.9979121,0.0005944096,0.0007938301,0.0001414703,0.00001254367,0.00007349886,0.0002410696,0.000003493634,0.0002275572],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006772404,"threshold_uncertainty_score":0.02172613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01778390504592575,"score_gpt":0.2946410852356914,"score_spread":0.2768571801897656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}